Brief: Vigil Neuroscience Expects To Report Phase 2 Ignite Results From All Patients In 20 Mg/KG And 40 Mg/KG Cohorts At 6 Months In Q3 Of 2024
16/11/2023 22:03
Nov 16 (Reuters) - Vigil Neuroscience Inc VIGL.O :
* VIGIL NEUROSCIENCE REPORTS POSITIVE INTERIM DATA FROM
PHASE 2
IGNITE PROOF-OF-CONCEPT CLINICAL TRIAL EVALUATING ILUZANEBART
(VGL101) AS A TREATMENT FOR ALSP AND FROM ONGOING NATURAL
HISTORY STUDY ILLUMINATE
* VIGIL NEUROSCIENCE INC - EXPECTS TO REPORT PHASE 2 IGNITE
RESULTS FROM ALL PATIENTS IN 20 MG/KG AND 40 MG/KG COHORTS AT 6
MONTHS IN Q3 OF 2024
Source text for Eikon: ID:nGNX6brb83
Further company coverage: VIGL.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Vigil Neuroscience
See all newsVigil Neuroscience Inc reports results for the quarter ended June 30 - Earnings Summary
Vigil Neuroscience Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
U.S. RESEARCH ROUNDUP-Ralph Lauren, Vigil Neuroscience, Workday
Deals of the day-Mergers and acquisitions